Home > Cannabis Research > Is Cannabis Addictive?

Is Cannabis Addictive?

The Science of Cannabis Use Disorder

Separating myth from evidence: what decades of research reveal about marijuana addiction, dependence, and the neurobiology of cannabis use disorder

3 in 10

Users Develop CUD

NIDA; Hasin et al.

1 in 6

Teen Users Develop CUD

AACAP

4% → 25%

THC Potency Increase

1995 to Present

FDA-Approved CUD Medications

As of 2026

The question "Is cannabis addictive?" has a clear, evidence-based answer: yes. Approximately 22-30% of people who use cannabis develop cannabis use disorder (CUD), a clinically recognized condition in the DSM-5. For those who begin using before age 18, the risk is even higher -- roughly 1 in 6. This page examines the neurobiology of cannabis addiction, who is most at risk, why the "it's not addictive" myth persists, and what treatment options are available.

Schedule Consultation The Neuroscience

Quick Answer: Is Cannabis Addictive?
Is it addictive?	Yes. Cannabis use disorder (CUD) is a DSM-5 diagnosis affecting 22-30% of users (NIDA). Cannabis produces tolerance, withdrawal, craving, and compulsive use -- the hallmarks of addiction.
How common?	3 in 10 adult users develop CUD. 1 in 6 adolescent users develop CUD. 9.8% of all substance use treatment admissions are cannabis-related (TEDS 2023).
Who is at risk?	Those who start before age 18, daily users, people using high-potency products (concentrates, dabs), those with family history of addiction, and people with co-occurring mental health conditions (ADHD, anxiety, depression).
Treatment?	CBT, Motivational Enhancement Therapy, Contingency Management. No FDA-approved medication exists yet. Dr. Sultan's PAWS project at Columbia is developing a digital therapeutic for CUD.
Expert	Ryan S. Sultan, MD -- NIH NIDA K12 researcher, Assistant Professor of Clinical Psychiatry at Columbia University Irving Medical Center

What Is Cannabis Use Disorder?

Cannabis use disorder (CUD) is a medical diagnosis recognized by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). It describes a problematic pattern of cannabis use leading to clinically significant impairment or distress. CUD is not defined by how much or how often someone uses cannabis -- it is defined by the consequences of that use and the individual's inability to control it.

The DSM-5 replaced the older DSM-IV distinctions between "cannabis abuse" and "cannabis dependence" with a single diagnosis on a spectrum. CUD severity is determined by the number of criteria met within a 12-month period: mild (2-3 criteria), moderate (4-5 criteria), or severe (6 or more criteria out of 11 total).

In common language, CUD is what people mean when they say "marijuana addiction," "cannabis addiction," or "weed dependence." While those terms are less precise than the clinical diagnosis, they describe the same core phenomenon: a loss of volitional control over cannabis use that causes harm. CUD is a medical condition -- not a moral failing. It involves measurable changes in brain chemistry and neural circuitry that make cessation genuinely difficult without support.

I see patients with CUD in my clinic every week. Many of them are highly intelligent, successful individuals who started using cannabis recreationally and, over months or years, found themselves unable to stop despite wanting to. The gradual onset is part of what makes cannabis addiction so insidious -- and part of why the myth that it is "not addictive" has been so difficult to dispel.

The "It's Not Addictive" Myth vs. the Evidence

Perhaps no myth in substance use has been as durable -- or as harmful -- as the belief that cannabis is not addictive. This belief persists despite decades of rigorous scientific evidence to the contrary. Understanding why the myth endures is important for understanding the current landscape of cannabis use and its consequences.

Why the Myth Persists

Several factors contribute to the persistence of this myth:

Comparison to "harder" drugs: Cannabis withdrawal is less physically dramatic than opioid or alcohol withdrawal. People equate "not as bad" with "not addictive at all." This is a logical error. Nicotine withdrawal is also relatively mild physically, yet no one disputes that tobacco is addictive.
Legalization messaging: The movement toward legalization has, understandably, emphasized safety and minimized risk. Advocacy language often conflates "safer than alcohol" with "safe" and "less addictive than heroin" with "not addictive."
Gradual onset: Unlike cocaine or methamphetamine, cannabis addiction develops gradually -- often over months or years. Users rarely have a sudden, dramatic realization that they have lost control. The progression is slow enough to be rationalized away.
Historical potency: Cannabis in the 1970s and 1980s contained approximately 2-4% THC. At those potencies, rates of addiction were lower. Today's products regularly contain 15-25% THC, and concentrates can exceed 90% THC. The drug has fundamentally changed, but the cultural perception has not caught up.
Personal experience bias: Many people use cannabis without developing CUD (70-78% of users do not). They generalize from their own experience -- "I use it and I'm fine" -- without recognizing that 22-30% of users are not fine.

What the Evidence Actually Shows

The scientific evidence on cannabis addiction is unambiguous:

NIDA: 22-30% of cannabis users develop cannabis use disorder (Hasin et al., 2015, JAMA Psychiatry).
AACAP: 1 in 6 adolescents who use cannabis develop CUD -- a higher rate than adults, reflecting adolescent brain vulnerability.
NESARC data (Hasin et al., 2016): Past-year cannabis use disorder prevalence doubled in the U.S. between 2001-2002 and 2012-2013, coinciding with increasing potency and decreasing risk perception.
DSM-5 recognition (2013): Cannabis withdrawal was formally codified as a diagnostic entity, based on extensive research demonstrating a reproducible, clinically significant withdrawal syndrome.
Neuroimaging research: PET and fMRI studies demonstrate measurable CB1 receptor downregulation, altered dopamine signaling, and changes in prefrontal cortex function in chronic cannabis users -- the same types of neural changes seen in other addictions.
TEDS 2023: Cannabis is the primary substance in 9.8% of all substance use treatment admissions in the United States, making it the third most common substance of abuse after alcohol and opioids.

Clinical Bottom Line: Telling someone that cannabis is "not addictive" is not just inaccurate -- it is potentially harmful. It delays help-seeking, undermines the experiences of the millions of people who do develop CUD, and creates a false sense of security that can facilitate escalation of use. The question is not whether cannabis is addictive. The question is why, for whom, and how we treat it effectively.

The Neurobiology of Cannabis Addiction

To understand why cannabis is addictive, you need to understand the endocannabinoid system (ECS) -- the brain system that THC hijacks. The ECS is one of the most important neurotransmitter systems in the human body, involved in regulating mood, appetite, pain, sleep, memory, and reward.

The Endocannabinoid System

The ECS consists of three core components:

Endocannabinoids: The body's naturally produced cannabis-like molecules. The two primary endocannabinoids are anandamide (named after the Sanskrit word for bliss) and 2-arachidonoylglycerol (2-AG). These molecules are produced on demand and act as retrograde neurotransmitters -- they travel "backward" across synapses to modulate the release of other neurotransmitters.
Cannabinoid receptors: CB1 receptors are densely concentrated in the brain -- particularly in the hippocampus (memory), prefrontal cortex (decision-making), basal ganglia (movement), amygdala (emotion), and the mesolimbic dopamine pathway (reward). CB2 receptors are found primarily in immune cells and peripheral tissues.
Metabolic enzymes: FAAH (fatty acid amide hydrolase) breaks down anandamide, and MAGL (monoacylglycerol lipase) breaks down 2-AG. These enzymes ensure that endocannabinoid signaling is precisely regulated and time-limited.

How THC Hijacks the System

Delta-9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis, is a partial agonist at CB1 receptors. It mimics anandamide but with critical differences: THC is introduced in far larger quantities than the body would ever produce naturally, it is not broken down by the same rapid enzymatic processes, and it persists in the system much longer due to its fat solubility.

When THC floods CB1 receptors, it triggers a cascade of downstream effects including dopamine release in the nucleus accumbens -- the brain's reward center. This is the same reward circuit activated by all drugs of abuse, including alcohol, cocaine, opioids, and nicotine. The dopamine surge produces the subjective "high" and reinforces the behavior of using cannabis.

The Three Stages of Addiction

Cannabis addiction follows the same three-stage neurobiological cycle described for all substance use disorders (Koob & Volkow, 2016, New England Journal of Medicine):

Binge/Intoxication: THC activates the reward system, producing euphoria and reinforcing use. With repeated exposure, the brain begins to adapt.
Withdrawal/Negative Affect: As the brain downregulates CB1 receptors and reduces natural endocannabinoid production (tolerance), the absence of THC produces a negative emotional state -- irritability, anxiety, insomnia, dysphoria. The individual now uses cannabis not just for pleasure but to avoid feeling bad. This is the critical transition from recreational use to dependence.
Preoccupation/Anticipation: Chronic stress and altered prefrontal cortex function impair executive control and decision-making. The individual experiences craving -- an intense, intrusive urge to use -- and their ability to resist that urge is compromised. This is the stage where relapse becomes most likely, even after periods of abstinence.

Tolerance and CB1 Receptor Downregulation

Chronic cannabis use leads to CB1 receptor downregulation -- a well-documented phenomenon in which the brain reduces both the number and the sensitivity of CB1 receptors in response to persistent overstimulation by THC. PET imaging studies (D'Souza et al., 2016; Hirvonen et al., 2012) have shown that chronic cannabis users have significantly fewer available CB1 receptors compared to non-users, particularly in cortical regions.

This downregulation is the biological basis of tolerance: users need progressively more cannabis to achieve the same effect. It is also the biological basis of withdrawal: when cannabis is removed, the depleted endocannabinoid system cannot maintain normal functioning. The brain has been relying on exogenous THC to do what anandamide and 2-AG are supposed to do, and when the THC is gone, there is a functional deficit.

The good news: CB1 receptor density begins to recover within approximately 2 days of abstinence and returns to normal levels within approximately 4 weeks in most users (D'Souza et al., 2016). This recovery timeline roughly parallels the resolution of cannabis withdrawal symptoms -- and provides a biological basis for encouraging patients that the discomfort of early abstinence is temporary.

DSM-5 Diagnostic Criteria for Cannabis Use Disorder

The DSM-5 specifies 11 diagnostic criteria for cannabis use disorder. A diagnosis requires meeting at least 2 criteria within a 12-month period. For a detailed discussion of each criterion, see our comprehensive CUD guide.

The 11 Criteria (Summary)

Using cannabis in larger amounts or longer than intended
Persistent desire or unsuccessful efforts to cut down
Spending excessive time obtaining, using, or recovering from cannabis
Craving or strong urge to use cannabis
Failure to fulfill major obligations at work, school, or home
Continued use despite social or interpersonal problems
Giving up important activities because of cannabis use
Using in physically hazardous situations
Continued use despite known physical or psychological harm
Tolerance (needing more to achieve the same effect)
Withdrawal (experiencing symptoms when stopping)

Severity Classification

Mild CUD: 2-3 criteria met
Moderate CUD: 4-5 criteria met
Severe CUD: 6 or more criteria met

It is worth noting that many individuals who meet criteria for CUD do not recognize it. The most common rationalization I hear in clinical practice is, "But I can stop whenever I want -- I just don't want to." When I ask those individuals to try stopping for two weeks, the answer usually reveals whether that belief is accurate. Most cannot do it without experiencing significant discomfort or reverting to use within days.

How Common Is Cannabis Addiction?

Cannabis addiction is significantly more common than most people realize. The cultural normalization of cannabis use -- combined with the "not addictive" myth -- has created a substantial gap between public perception and epidemiological reality.

22-30%

Of All Cannabis Users

NIDA estimates that roughly 3 in 10 people who use cannabis will develop CUD. The Hasin et al. (2015) NESARC analysis in JAMA Psychiatry placed the rate at approximately 30% among past-year users.

1 in 6

Adolescent Users

AACAP reports that approximately 17% of adolescents who use cannabis develop CUD. The developing adolescent brain is more susceptible to the neuroadaptive changes that produce dependence.

16.2M

Americans with CUD

The 2022 National Survey on Drug Use and Health (NSDUH) estimated that 16.2 million Americans aged 12 and older met criteria for cannabis use disorder in the past year.

CUD Prevalence Doubled

Past-year CUD prevalence doubled between 2001-2002 and 2012-2013 (Hasin et al., 2016, JAMA Psychiatry), driven by increasing potency and decreasing risk perception.

To put these numbers in context: the addiction rate for cannabis (22-30%) is comparable to that of alcohol (approximately 15%) and lower than nicotine (approximately 32%). But the fact that cannabis is "less addictive than nicotine" does not mean it is "not addictive" -- a distinction that is frequently lost in public discourse. With over 50 million Americans reporting past-year cannabis use, even a 22% CUD rate translates to millions of affected individuals.

Risk Factors for Cannabis Addiction

Not everyone who uses cannabis becomes addicted. Understanding who is at greatest risk -- and why -- is critical for prevention, early identification, and targeted intervention.

1. Age of Onset

This is the single most important risk factor. Individuals who begin using cannabis before age 18 -- and especially before age 15 -- face substantially higher rates of CUD. The adolescent brain is undergoing critical development of the prefrontal cortex, which governs impulse control, judgment, and decision-making. THC exposure during this developmental window disrupts normal maturation of both the endocannabinoid system and frontostriatal circuits, producing lasting vulnerability to compulsive use. AACAP estimates that 1 in 6 adolescent users develops CUD, compared to approximately 1 in 10 adult-onset users.

2. Frequency and Pattern of Use

Daily or near-daily cannabis use is the strongest behavioral predictor of CUD. Regular, heavy use accelerates CB1 receptor downregulation and the development of tolerance. The progression from weekly to daily use often happens gradually and is frequently rationalized ("I just use it to unwind at night"). By the time tolerance has developed, the neurobiological changes underlying dependence are already in place.

3. THC Potency

Today's cannabis is not your parents' marijuana. Average THC content has risen from approximately 4% in 1995 to 15-25% in current flower products. Concentrates (dabs, shatter, wax) can contain 60-90% THC, and vape cartridges often exceed 80%. Higher potency means faster tolerance development, more severe withdrawal, and higher addiction rates. The Freeman et al. (2020) study in Lancet Psychiatry demonstrated a clear dose-response relationship between cannabis potency and dependence. For more on this topic, see our THC potency analysis.

4. Genetic Vulnerability

Twin studies estimate that genetic factors account for 50-70% of the variance in vulnerability to cannabis use disorder (Verweij et al., 2010). Specific genetic variants in the CNR1 gene (encoding the CB1 receptor), FAAH gene (encoding the enzyme that breaks down anandamide), and genes related to dopamine signaling have been associated with increased CUD risk. Family history of any substance use disorder -- not just cannabis -- is a significant risk factor.

5. Co-Occurring Mental Health Conditions

Individuals with ADHD, anxiety disorders, depression, PTSD, and other mental health conditions are at significantly elevated risk for CUD. The self-medication hypothesis explains part of this: people use cannabis to manage symptoms of untreated or undertreated psychiatric conditions, develop tolerance, and progress to dependence. In my practice, the ADHD-cannabis connection is particularly common -- adolescents and young adults with undiagnosed or undertreated ADHD frequently turn to cannabis for its calming effects, only to develop CUD that makes both conditions harder to treat. For more on this intersection, see our ADHD and substance use page.

6. Method of Use

Routes of administration that deliver THC more rapidly to the brain carry higher addiction potential. Smoking and vaping produce near-immediate effects (within seconds), which strengthens the reinforcement loop. Concentrates (dabbing) deliver massive THC doses rapidly. Edibles have a delayed onset (30-90 minutes) but can lead to taking more than intended due to the lag time, and the prolonged high can accelerate tolerance development with regular use.

How Cannabis Addiction Compares to Other Substance Use Disorders

Cannabis use disorder is often compared to other substance use disorders -- sometimes accurately, sometimes misleadingly. Here is how CUD compares along key dimensions:

Dimension	Cannabis	Alcohol	Nicotine	Opioids
Addiction Rate (% of Users)	22-30%	~15%	~32%	~23-25%
Withdrawal Severity	Moderate	Severe (can be fatal)	Moderate	Severe
Overdose Lethality	Extremely rare	Common	Rare	Very common
FDA-Approved Medication	None	Yes (3+)	Yes (3+)	Yes (3+)
Speed of Dependence Onset	Months to years	Months to years	Weeks to months	Days to weeks
Cognitive Impairment	Moderate (partially reversible)	Severe (partially reversible)	Minimal	Moderate
Psychosis Risk	Significant (esp. high potency)	Yes (during withdrawal)	No	No

Several important patterns emerge from this comparison. Cannabis has a higher addiction rate than alcohol. Its withdrawal is less physically dangerous than alcohol or opioid withdrawal but is clinically significant and often underestimated. Crucially, cannabis is the only major substance of abuse with no FDA-approved medication for its use disorder -- a treatment gap that researchers, including our team at Columbia, are actively working to address. For more on how cannabis compares to alcohol specifically, see our marijuana vs. alcohol comparison.

Treatment Options for Cannabis Addiction

Cannabis use disorder is treatable. While there is no single "cure," evidence-based interventions can significantly reduce use, alleviate withdrawal symptoms, and help individuals regain control. The primary challenge is the lack of FDA-approved medications, which places the entire treatment burden on behavioral interventions and clinical support.

Evidence-Based Behavioral Treatments

Cognitive Behavioral Therapy (CBT)

CBT is the most extensively studied treatment for CUD. It teaches patients to identify triggers for use, develop alternative coping strategies, challenge cognitive distortions that maintain use ("I need it to relax"), and build skills for relapse prevention. CBT produces modest but significant reductions in cannabis use, with effects that tend to persist beyond the treatment period. The structured, skill-based nature of CBT makes it well-suited to the practical needs of CUD patients.

Motivational Enhancement Therapy (MET)

MET addresses a common challenge in CUD treatment: ambivalence about change. Many patients recognize that their cannabis use is causing problems but are not fully committed to stopping. MET uses motivational interviewing techniques to help patients explore their own reasons for change, resolve ambivalence, and build internal motivation. It is typically delivered in 2-4 sessions and is often combined with CBT.

Contingency Management (CM)

CM provides tangible rewards (vouchers, prizes, privileges) for verified abstinence, typically confirmed through urine drug testing. It is one of the most effective interventions for achieving initial abstinence. Research consistently shows that CM produces higher abstinence rates than other behavioral interventions alone, though effects can diminish after the incentives are removed. The combination of CM with CBT and MET tends to produce the most robust outcomes.

The Medication Gap

There are currently no FDA-approved medications for cannabis use disorder. This is one of the most significant unmet needs in addiction medicine. Several compounds are under investigation:

N-acetylcysteine (NAC): Showed promise in adolescent trials (Gray et al., 2012, American Journal of Psychiatry) but did not replicate in adult trials.
Gabapentin: Some evidence for reducing withdrawal symptoms and cannabis use in heavy users (Mason et al., 2012).
Nabiximols (Sativex): A THC/CBD combination spray being studied as a cannabis agonist replacement therapy (similar to methadone for opioids).
Fatty acid amide hydrolase (FAAH) inhibitors: Experimental compounds designed to boost natural endocannabinoid levels, potentially reducing craving without producing a high.

The absence of approved medications is a major reason why treatment completion rates for CUD are low -- only 36.8% of adolescents completed treatment between 2018-2021 (TEDS data). It is also why novel approaches, including digital therapeutics, are being explored. Our PAWS project at Columbia is developing a digital therapeutic specifically designed to address this treatment gap.

Managing Cannabis Withdrawal

Withdrawal is often the first barrier to successful treatment. Cannabis withdrawal -- formally recognized in the DSM-5 since 2013 -- affects a substantial proportion of regular users and includes irritability, anxiety, insomnia, decreased appetite, restlessness, depressed mood, and physical symptoms such as sweating and abdominal pain. Symptoms typically peak within the first 1-3 days and resolve within 1-2 weeks. For a comprehensive guide to withdrawal management, see our cannabis withdrawal page.

Although no medication is specifically approved for cannabis withdrawal, symptom-targeted approaches can help: sleep aids for insomnia, anti-nausea medication for GI symptoms, and short-term anxiolytics for severe anxiety. The most important intervention, in my clinical experience, is psychoeducation -- helping patients understand that withdrawal is temporary, that it has a predictable timeline, and that the discomfort is a sign that their brain is healing, not a sign that they "need" cannabis.

Dr. Sultan's Cannabis Research at Columbia

As an NIH NIDA K12-funded researcher at Columbia University Irving Medical Center, I focus on understanding cannabis use disorder across the lifespan -- with particular attention to adolescents and young adults, high-potency products, and the development of novel interventions.

Active Research Programs

PAWS Digital Therapeutic: Developing a digital intervention for cannabis use disorder and cannabis-related psychosis. This project addresses the critical treatment gap created by the absence of FDA-approved medications for CUD. The PAWS approach combines evidence-based behavioral strategies with digital delivery to improve access and adherence.
Pediatrics 2026 Study: Our recent publication examining cannabis use patterns and outcomes in pediatric populations, contributing to the evidence base on adolescent vulnerability to CUD.
Cardiovascular Risk Research: Our 2025 publication in JAMA Cardiology examining the cardiovascular effects of cannabis use, adding to the growing evidence that cannabis carries significant medical risks beyond addiction.

My research collaborators include Dr. Yasmin Hurd at Mount Sinai (a leading translational neuroscientist studying the endocannabinoid system and CBD's potential in addiction treatment), Dr. Sharon Levy at Harvard (an expert in adolescent substance use), Dr. Kevin Gray at the Medical University of South Carolina (who led the landmark NAC trial for adolescent CUD), and Dr. Carlos Blanco at NIDA (one of the foremost epidemiologists of substance use disorders).

In my clinical practice at Integrative Psych, I treat patients with CUD using the same evidence-based approaches described above. I am board-certified in both adult and child/adolescent psychiatry, which allows me to work with individuals across the age spectrum -- from adolescents whose parents are concerned about escalating use, to adults who have been using daily for decades and have developed severe CUD.

Frequently Asked Questions About Cannabis Addiction

Q: Is cannabis actually addictive?

A: Yes. Cannabis is addictive. Approximately 22-30% of people who use cannabis develop cannabis use disorder (CUD), a DSM-5-recognized condition characterized by tolerance, withdrawal, craving, and loss of control over use. The risk is higher for adolescents (1 in 6 users) and increases with higher-potency products, daily use, and earlier age of onset. Cannabis acts on the brain's endocannabinoid system, producing the same types of neuroadaptive changes seen in other addictions.

Q: What is cannabis use disorder?

A: Cannabis use disorder (CUD) is a DSM-5-defined medical condition in which an individual cannot stop using cannabis despite negative consequences. It is diagnosed when at least 2 of 11 criteria are met within a 12-month period, including using more than intended, inability to cut down, craving, tolerance, withdrawal, and continued use despite harm. CUD exists on a severity spectrum: mild (2-3 criteria), moderate (4-5), and severe (6+). See our comprehensive CUD guide for detailed criteria.

Q: How does cannabis addiction differ from other drug addictions?

A: Cannabis addiction shares core features with all substance use disorders -- loss of control, continued use despite consequences, tolerance, and withdrawal. It differs in several ways: withdrawal is less physically dangerous than alcohol or opioid withdrawal, dependence develops more gradually (months to years rather than days to weeks), there is no FDA-approved medication for CUD, and cultural normalization delays recognition. The addiction potential of cannabis (22-30%) is actually comparable to or higher than alcohol (approximately 15%).

Q: What are the signs of cannabis addiction?

A: Key signs include needing more cannabis to achieve the same effect (tolerance), experiencing irritability, insomnia, or anxiety when not using (withdrawal), using more or longer than intended, unsuccessful attempts to cut down, spending excessive time obtaining or using cannabis, giving up important activities, continuing use despite relationship or work problems, using in hazardous situations (e.g., before driving), and persistent craving for cannabis.

Q: Why do people think cannabis is not addictive?

A: The myth persists for several reasons: cannabis withdrawal is less physically dramatic than opioid or alcohol withdrawal; legalization advocacy has emphasized safety messaging; cannabis addiction develops gradually rather than rapidly; personal experience bias ("I use it and I'm fine") leads people to discount the 22-30% who develop CUD; and historical cannabis was lower in potency. Today's products contain 15-25% THC (up from 4% in 1995), and concentrates can exceed 90% THC. The scientific evidence is unambiguous.

Q: What happens in the brain during cannabis addiction?

A: THC floods CB1 receptors in the brain, triggering dopamine release in the reward center. With chronic use, the brain downregulates CB1 receptors and reduces natural endocannabinoid production. This produces tolerance (needing more to feel the same effect) and withdrawal (uncomfortable symptoms when not using, because the depleted endocannabinoid system cannot maintain normal function). PET studies show full CB1 receptor recovery takes approximately 4 weeks of abstinence.

Q: Who is most at risk for cannabis addiction?

A: The highest-risk groups include adolescents who begin using before age 18 (1 in 6 develop CUD), daily or near-daily users, people using high-potency THC products (concentrates, dabs, vape cartridges), individuals with a family history of substance use disorders, and people with co-occurring mental health conditions such as ADHD, anxiety, depression, or PTSD. Using cannabis as a primary coping mechanism also increases risk.

Q: Can cannabis addiction be treated?

A: Yes. Evidence-based treatments include Cognitive Behavioral Therapy (CBT), Motivational Enhancement Therapy (MET), and Contingency Management (CM). Combination approaches produce the best outcomes. No FDA-approved medication exists specifically for CUD, though several are under investigation. Dr. Sultan's PAWS project at Columbia is developing a digital therapeutic to address this treatment gap. Treatment completion rates remain a challenge, particularly for adolescents (only 36.8% completed treatment between 2018-2021 per TEDS data).

Related Resources

Cannabis Use Disorder: Full Guide

Complete DSM-5 diagnostic criteria, prevalence data, self-assessment checklist, and detailed treatment information.

Cannabis Use Disorder →

Cannabis Withdrawal Guide

Symptoms, timeline, treatment strategies, and what to expect during cannabis withdrawal.

Cannabis Withdrawal →

PAWS Digital Therapeutic

Dr. Sultan's innovative digital intervention for cannabis use disorder and cannabis-related psychosis.

PAWS Project →

Cannabis & Mental Health Hub

Comprehensive overview of cannabis research, including psychosis risk, brain effects, and treatment resources.

Cannabis Hub →

Concerned About Cannabis Addiction?

Dr. Ryan Sultan provides evidence-based evaluation and treatment for cannabis use disorder. As an NIH NIDA-funded researcher at Columbia University, he brings both clinical expertise and cutting-edge research knowledge to every patient interaction.

Schedule a Consultation

Telehealth appointments available | Board-Certified Psychiatrist | Columbia University Faculty

Contact

Schedule Consultation
ADHD Resources
Columbia University Irving Medical Center

The information on this page is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.